logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HER2+ metastatic breast cancer: neratinib is superior to lapatinib plus capecitabine

Phase 3 NALA is for patients previously treated with at least 2 HER2-directed regimens.